Surgical Science Sweden ABSUSRF -2.20%82 Peter Lynch Fair Value is $0.90 as of Jul. 10, 2026, which is 64% below its 10-year median of 2.47. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.24 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 170 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks worse than 79.41% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Surgical Science Sweden AB's PEG is 1. Surgical Science Sweden AB's 5-Year TTM EBITDA Growth Rate is 8.05.
Surgical Science Sweden AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.11. Therefore, the Peter Lynch Fair Value for today is $0.90.
The historical rank and industry rank for Surgical Science Sweden AB's Peter Lynch Fair Value or its related term are showing as below:
SUSRF'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.09 Med: 2.47 Max: 9.71
Current: 2.67
During the past 11 years, the highest Price to Peter Lynch Fair Value Ratio of Surgical Science Sweden AB was 9.71. The lowest was 1.09. And the median was 2.47.
SUSRF's Price-to-Peter-Lynch-Fair-Value is ranked worse than 79.41% of 170
companies
in the Healthcare Providers & Services industry
Industry Median: 1.185
vs SUSRF: 2.67
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Surgical Science Sweden AB (OTCPK:SUSRF) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 8.05 instead of 15 in this case.
Surgical Science Sweden AB's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
4.00
/
0.90
=
4.44
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Peter Lynch Fair Value Related Terms
Surgical Science Sweden AB Peter Lynch Fair Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Peter Lynch Fair Value Chart
SUSRF vs VEEV, BTSG, TEM: Peter Lynch Fair Value Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Price-to-Peter-Lynch-Fair-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Price-to-Peter-Lynch-Fair-Value falls into.
Surgical Science Sweden AB's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.11.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
Surgical Science Sweden AB (SUSRF) has a Peter Lynch Fair Value of $0.90 as of Jul. 10, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Surgical Science Sweden AB and its competitors. This is 64% below median its historical median of 2.47. Over the past decade, Surgical Science Sweden AB's Peter Lynch Fair Value has ranged from 1.09 to 9.71. According to the industry distribution chart, Surgical Science Sweden AB ranks #135 out of 170 companies in the Healthcare Providers & Services industry, placing it in the top 79.4%.
Is Surgical Science Sweden AB's Peter Lynch Fair Value too high?
Surgical Science Sweden AB's current Peter Lynch Fair Value of $0.90 is 64% below median its 10-year median of 2.47. Over the past 10 years, this metric has ranged from a low of 1.09 to a high of 9.71. The Healthcare Providers & Services industry median Peter Lynch Fair Value is 1.19. Surgical Science Sweden AB's value of $0.90 is 24.1% below this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #135 out of 170 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Peter Lynch Fair Value compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #135 out of 170 companies for Peter Lynch Fair Value. This places Surgical Science Sweden AB in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.19. Surgical Science Sweden AB's value of $0.90 is 24.1% below this benchmark. Historically, Surgical Science Sweden AB's own Peter Lynch Fair Value has ranged from 1.09 to 9.71 over the past decade. While the company's 10-year median is 2.47 vs. the industry median of 1.19, Surgical Science Sweden AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Healthcare Providers & Services company?
The median Peter Lynch Fair Value among Healthcare Providers & Services companies is 1.19, based on 170 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Peter Lynch Fair Value of $0.90 is 24.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Peter Lynch Fair Value is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Peter Lynch Fair Value is $0.90, which is 64% below median its own 10-year median of 2.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.24, compared to a current price of $4.00 — trading 71.9% below its estimated fair value. The current Peter Lynch Fair Value is $0.90, which is 64% below median its 10-year median of 2.47 and 24.1% below the Healthcare Providers & Services industry median of 1.19. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Peter Lynch Fair Value is $0.90 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 71.9% below its estimated GF Value™ of $14.24.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Peter Lynch Fair Value: $0.90 (64% below median its 10-year median of 2.47)
GF Value™: $14.24 vs. price of $4.00 (71.9% below fair value)
Industry Position: 24.1% below the Healthcare Providers & Services median (#135 of 170)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
